Acute Elevation in Liver Function Tests and Thrombocytopenia

Immediate Medication Assessment

The American College of Rheumatology recommends holding or decreasing the dose of hepatotoxic immunosuppressants, such as methotrexate, sulfasalazine, or leflunomide, immediately when clinically relevant elevation in liver function tests occurs alongside decreased platelet count 1, 2, 3
For patients on methotrexate, the American College of Rheumatology advises against testing within 2 days of the last dose, as liver function tests may be transiently elevated 4
The American College of Rheumatology suggests considering a temporary hold on leflunomide if alanine transaminase (ALT) is greater than 3 times the upper limit of normal (ULN), and using cholestyramine or activated charcoal to accelerate elimination if needed 3, 4
The American College of Rheumatology recommends ensuring patients on methotrexate are also on folic or folinic acid to mitigate adverse events 1, 4

A platelet count less than 50×10⁹/L with elevated liver function tests requires urgent evaluation for bleeding risk and potential need for procedure modifications, according to the International Society on Thrombosis and Haemostasis 7
The European Association for the Study of the Liver recommends checking for signs of acute liver failure, including coagulopathy, altered mental status, or severe synthetic dysfunction 8

The American Association for the Study of Liver Diseases recommends ordering a repeat complete blood count (CBC) with differential and comprehensive metabolic panel to confirm findings and assess renal function 4, 8
The American Society of Hematology suggests performing a peripheral blood smear to exclude pseudothrombocytopenia and assess platelet morphology 6

The International Society on Thrombosis and Haemostasis recommends continuing full therapeutic anticoagulation if indicated without platelet transfusion for platelet counts greater than or equal to 50×10⁹/L 7
For platelet counts between 25-50×10⁹/L, the International Society on Thrombosis and Haemostasis suggests reducing anticoagulation to 50% therapeutic dose or prophylactic dose low molecular weight heparin (LMWH) if anticoagulation is required 7

The American College of Rheumatology recommends rechecking CBC and liver function tests within 1-2 weeks to confirm improvement after holding causative medication 1, 4
The American College of Rheumatology advises resuming medication at a reduced dose only after normalization of labs and with close monitoring every 3-4 months 1, 4